Improving patient informed consent for haemophilia gene therapy: the case for change.
Laurence WoollardRichard GormanDakota J RosenfeltPublished in: Therapeutic advances in rare disease (2021)
Gene therapy is the process of replacing faulty genes with healthy ones. In haemophilia, gene therapy involves introducing a working copy of the gene for the clotting factor that patients are missing. Following treatment, patients should begin producing their own clotting factor normally. However, people living with haemophilia (PwH) need to be fully informed regarding the potential benefits and risks of gene therapy and what this means for them, whether as part of a research study or routine medical care.Patients must be respected and supported to make decisions about their own health and wellbeing, recognising their legal and moral right to set personal goals and make treatment choices. For this to happen in practice, patients should be aware of their individual health needs, understand the effects of treatment and consider lifestyle preferences in relation to their decisions. This article attempts to describe how informed consent is obtained in haemophilia gene therapy clinical trials, what affects a patient's ability to make decisions and the availability of information and support to respect and protect the interests of PwH.Regulators responsible for approving medical products have published guidance on informed consent for physicians and pharmaceutical manufacturers in haemophilia, including for gene therapy. Recommendations have been made about the best ways for PwH to discuss gene therapy with their physicians. Yet, poor communication of complex topics, such as gene therapy, can be problematic, especially if patients lack the skills and confidence to understand and discuss the science, or for physicians with limited time in clinic.We propose strategies to improve the consent process, so patients can feel more able to make informed decisions about new treatments. Further research is needed to find new, creative approaches for educating patients and ensuring that the informed consent process for gene therapy in haemophilia is ethical.
Keyphrases
- gene therapy
- end stage renal disease
- chronic kidney disease
- ejection fraction
- newly diagnosed
- clinical trial
- primary care
- randomized controlled trial
- prognostic factors
- peritoneal dialysis
- public health
- risk assessment
- climate change
- study protocol
- genome wide
- patient reported
- quality improvement
- metabolic syndrome
- decision making
- patient reported outcomes
- combination therapy
- gene expression
- type diabetes
- clinical practice
- smoking cessation
- phase ii
- copy number
- health promotion